


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:24Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12407638" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12407638</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>futoncol</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Future Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Future Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">3069</journal-id><journal-id journal-id-type="pmc-domain">futoncol</journal-id><journal-title-group><journal-title>Future Oncology</journal-title></journal-title-group><issn pub-type="ppub">1479-6694</issn><issn pub-type="epub">1744-8301</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12407638</article-id><article-id pub-id-type="pmcid-ver">PMC12407638.1</article-id><article-id pub-id-type="pmcaid">12407638</article-id><article-id pub-id-type="pmcaiid">12407638</article-id><article-id pub-id-type="pmid">40782019</article-id><article-id pub-id-type="doi">10.1080/14796694.2025.2542108</article-id><article-id pub-id-type="publisher-id">2542108</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Meta-Analysis</subject></subj-group></article-categories><title-group><article-title>Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting</article-title><alt-title alt-title-type="left-running-head">R. M. NAVARI ET AL.</alt-title><alt-title alt-title-type="right-running-head">FUTURE ONCOLOGY</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8513-896X</contrib-id><name name-style="western"><surname>Navari</surname><given-names initials="RM">Rudolph M.</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-6208-4502</contrib-id><name name-style="western"><surname>Tyler</surname><given-names initials="T">Timothy</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4624-7119</contrib-id><name name-style="western"><surname>Inui</surname><given-names initials="N">Naoki</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4171-454X</contrib-id><name name-style="western"><surname>Iihara</surname><given-names initials="H">Hirotoshi</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-5302-117X</contrib-id><name name-style="western"><surname>Bonizzoni</surname><given-names initials="E">Erminio</given-names></name><xref rid="aff0005" ref-type="aff">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4156-9212</contrib-id><name name-style="western"><surname>Park</surname><given-names initials="YH">Yeon Hee</given-names></name><xref rid="aff0006" ref-type="aff">
<sup>f</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6710-4814</contrib-id><name name-style="western"><surname>Rugo</surname><given-names initials="HS">Hope S.</given-names></name><xref rid="aff0007" ref-type="aff">
<sup>g</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3674-3573</contrib-id><name name-style="western"><surname>Roeland</surname><given-names initials="EJ">Eric J.</given-names></name><xref rid="aff0008" ref-type="aff">
<sup>h</sup>
</xref></contrib><aff id="aff0001"><label>a</label>Center for Global Cancer Control, <institution-wrap><institution>World Health Organization</institution></institution-wrap>, <city>Mount Olive</city>, <state>AL</state>, <country>USA</country></aff><aff id="aff0002"><label>b</label>Comprehensive Cancer Center, <institution-wrap><institution>Desert Regional Medical Center</institution></institution-wrap>, <city>Palm Springs</city>, <state>CA</state>, <country>USA</country></aff><aff id="aff0003"><label>c</label>Second Division, Department of Internal Medicine, <institution-wrap><institution>Hamamatsu University School of Medicine</institution></institution-wrap>, <city>Hamamatsu</city>, <country>Japan</country></aff><aff id="aff0004"><label>d</label>Department of Pharmacy, <institution-wrap><institution>Gifu University Hospital</institution></institution-wrap>, <city>Gifu</city>, <country>Japan</country></aff><aff id="aff0005"><label>e</label><institution-wrap><institution>RIDE2Med Foundation</institution></institution-wrap>, <city>Milan</city>, <country>Italy</country></aff><aff id="aff0006"><label>f</label>Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, <institution-wrap><institution>Sungkyunkwan University School of Medicine</institution></institution-wrap>, <city>Seoul</city>, <country>Republic of Korea</country></aff><aff id="aff0007"><label>g</label><institution-wrap><institution>University of California San Francisco Helen Diller Family Comprehensive Cancer Center</institution></institution-wrap>, <city>San Francisco</city>, <state>CA</state>, <country>USA</country></aff><aff id="aff0008"><label>h</label>Knight Cancer Institute, <institution-wrap><institution>Oregon Health and Science University</institution></institution-wrap>, <city>Portland</city>, <state>OR</state>, <country>USA</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Rudolph M. Navari <email xlink:href="mailto:rmnavari@gmail.com">rmnavari@gmail.com</email> Center for Global Cancer Control, World Health Organization, <addr-line>4518 Crown Point Lane</addr-line>, <city>Mount Olive</city>, <state>AL</state><postal-code>35117</postal-code></corresp><fn id="an0002" fn-type="current-aff"><p>Present affiliation for Hope S. Rugo is Department of Medical Oncology &amp; Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>9</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><volume>21</volume><issue>21</issue><issue-id pub-id-type="pmc-issue-id">496179</issue-id><fpage seq="13">2823</fpage><lpage>2833</lpage><pub-history><event event-type="pmc-release"><date><day>09</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 16:25:19.050"><day>04</day><month>09</month><year>2025</year></date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>20</day><month>8</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>20</day><month>8</month><year>2025</year></date></event><event event-type="received"><date><day>11</day><month>12</month><year>2024</year></date></event><event event-type="accepted"><date><day>29</day><month>7</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="IFON_21_2542108.pdf"/><self-uri content-type="pdf" xlink:href="IFON_21_2542108.pdf"/><abstract><title>ABSTRACT</title><sec><title>Aim</title><p>Because no conclusive data demonstrate superiority among NK<sub>1</sub> receptor antagonists (RA), existing antiemetic guidelines regard them as interchangeable. This individual patient data (IPD) meta-analysis compared the efficacy of NEPA (netupitant/fosnetupitant) and aprepitant/fosaprepitant-based regimens in preventing chemotherapy-induced nausea and vomiting (CINV).</p></sec><sec><title>Materials &amp; Methods</title><p>Head-to-head comparative studies published between 2003 and 2022 that evaluated antiemetic prophylaxis of aprepitant or fosaprepitant versus oral or intravenous (IV) NEPA in patients with various cancers receiving highly (HEC) or moderately emetogenic chemotherapy (MEC) were identified through a literature search. We combined individual patient data to assess complete response (no emesis/no rescue medication) and no significant nausea using a two-stage approach.</p></sec><sec><title>Results</title><p>A total of six studies involving 2,767 patients were included evaluating NEPA plus dexamethasone versus aprepitant/fosaprepitant plus any 5-HT<sub>3</sub>RA plus dexamethasone for patients with cancer receiving HEC/MEC. Complete response and no significant nausea rates were similar during the acute (0&#8211;24&#8201;h) phase but NEPA showed significantly higher rates than aprepitant during the delayed (&#8201;&gt;&#8201;24&#8211;120&#8201;h) and overall (0&#8211;120&#8201;h) phases and on Days 3&#8211;5 following chemotherapy.</p></sec><sec><title>Conclusion</title><p>Improved CINV prevention was observed with NEPA-based regimens, particularly during Days 3&#8211;5, highlighting its potential for managing prolonged nausea and vomiting associated with emerging anticancer targeted therapies.</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>Plain Language Summary</title><p>This study examined two types of medicine to help cancer patients feel less sick during chemotherapy. Both types try to stop nausea and vomiting. One kind is called NEPA, and the other is called aprepitant. Both include drugs taken by mouth or given through an IV. All patients also took other common medicines to help with side effects. The researchers looked at six studies with a total of 2,767 patients. They wanted to see which medicine worked better. On the first day of chemotherapy, both types worked about the same. But in the days after chemotherapy, NEPA worked better. It helped prevent vomiting and more severe nausea. It also meant fewer people needed extra medicine to feel better. This improvement was true from day 2 to day 5 after treatment. The study shows that NEPA may give better long-term relief from chemotherapy side effects, which may be especially helpful for patients who are using newer cancer drugs that can cause longer-lasting nausea.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>NEPA</kwd><kwd>netupitant</kwd><kwd>palonosetron</kwd><kwd>aprepitant</kwd><kwd>CINV</kwd><kwd>nausea</kwd><kwd>vomiting</kwd><kwd>antiemetic</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution-wrap><institution>Helsinn</institution><institution-id institution-id-type="open-funder-registry">10.13039/100008129</institution-id></institution-wrap></funding-source></award-group><funding-statement>This IPD meta-analysis was sponsored by Helsinn Healthcare SA, Lugano, Switzerland.</funding-statement></funding-group></support-group><counts><fig-count count="3"/><table-count count="4"/><ref-count count="50"/><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><label>1.</label><title>Introduction</title><p>Major advances in antiemetic research have led to considerable progress in the prevention of nausea and vomiting associated with emetogenic chemotherapy. While current antiemetic therapies have substantially improved outcomes in controlling vomiting, optimally managing nausea, particularly in the delayed phase (&#8201;&gt;&#8201;24&#8211;120&#8201;hours post-chemotherapy) and beyond remains a persistent challenge [<xref rid="cit0001" ref-type="bibr">1</xref>]. Additionally, antibody-drug conjugates (ADCs) are a cornerstone in a rapidly expanding era of targeted therapy. Emerging data on some ADCs suggests that not only are nausea and vomiting among the most frequent treatment-related adverse events but nausea, in particular, can last well into the long-delayed phase (beyond Day 5) [<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0003" ref-type="bibr">3</xref>]. There is a critical need to educate clinicians on the emetogenicity of ADCs and the appropriate antiemetic prophylaxis in this setting [<xref rid="cit0004" ref-type="bibr">4</xref>].</p><p>Currently, four classes of drugs are recommended by antiemetic guidelines as prophylaxis for chemotherapy-induced nausea and vomiting (CINV): neurokinin-1 (NK<sub>1</sub>) receptor antagonists (RAs), 5-hydroxytryptamine-3 (5-HT<sub>3</sub>) RAs, corticosteroids (mainly dexamethasone), and psychotropics (mainly olanzapine). For adult patients, recommendations in evidence-based antiemetic guidelines from various cancer associations include prophylaxis with combinations of an NK<sub>1</sub>RA, 5-HT<sub>3</sub>RA, a corticosteroid (primarily dexamethasone), and olanzapine for patients receiving highly emetogenic chemotherapy (HEC) [<xref rid="cit0005" ref-type="bibr">5&#8211;7</xref>]. An NK<sub>1</sub>RA regimen is also recommended for patients receiving carboplatin-based regimens (at an area under curve [AUC] &#8805;4 [<xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0007" ref-type="bibr">7</xref>] or&#8201;&gt;&#8201;5&#8201;mg/mL/min dose [<xref rid="cit0008" ref-type="bibr">8</xref>]), oxaliplatin (if female and &#8804;50&#8201;years [<xref rid="cit0008" ref-type="bibr">8</xref>]), and those receiving moderately emetogenic chemotherapy (MEC) who have CINV risk factors, or for whom CINV was not controlled following prophylaxis with a 5-HT<sub>3</sub> RA and dexamethasone alone [<xref rid="cit0007" ref-type="bibr">7</xref>].</p><p>NK<sub>1</sub> RAs approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are included in the major antiemetic guidelines: aprepitant for oral administration (FDA and EMA approval in 2003) and its water-soluble pro-drug, fosaprepitant, for intravenous administration (FDA and EMA approval in 2008); netupitant for oral administration and its water-soluble pro-drug, fosnetupitant, for intravenous administration; and rolapitant for oral administration (FDA approval in 2015 and EMA approval in 2017). Netupitant and fosnetupitant are available as unique fixed-combinations with the 5-HT<sub>3</sub> RA, palonosetron (referred to as NEPA) for oral (FDA approval in 2014; EMA approval in 2015) and intravenous (FDA approval in 2018; EMA approval in 2019) administration. Fosnetupitant is additionally available as a standalone agent for intravenous (IV) infusion in Japan (Pharmaceuticals and Medical Devices Agency [PMDA] approval in 2022). Aprepitant, rolapitant, and oral NEPA regimens were approved based on studies showing superiority over a 5-HT<sub>3</sub> RA/dexamethasone regimen [<xref rid="cit0009" ref-type="bibr">9&#8211;12</xref>], while IV fosaprepitant and IV NEPA were approved based on showing pharmacokinetic bioequivalence and comparable efficacy/safety to oral aprepitant and oral NEPA, respectively [<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0013" ref-type="bibr">13</xref>]. While superiority was seen for complete response (i.e., no emesis and no use of rescue medication) for 5&#8201;days post-chemotherapy, the primary efficacy endpoint in all NK<sub>1</sub> RA registration studies, consistent superiority in the control of nausea was not observed for all NK<sub>1</sub> RAs [<xref rid="cit0001" ref-type="bibr">1</xref>]. National Comprehensive Cancer Network (NCCN) guidelines acknowledge this observation in their statement that &#8220;data suggest that oral rolapitant and netupitant are effective at decreasing delayed nausea&#8221; [<xref rid="cit0007" ref-type="bibr">7</xref>].</p><p>The addition of an NK<sub>1</sub> RA to a 5-HT<sub>3</sub> RA and dexamethasone has consistently demonstrated clear antiemetic benefits across numerous trials [<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0011" ref-type="bibr">11&#8211;13</xref>] with further validation from several systematic reviews and meta-analyses [<xref rid="cit0014" ref-type="bibr">14&#8211;16</xref>]; however, data directly comparing individual NK<sub>1</sub> RAs is limited [<xref rid="cit0015" ref-type="bibr">15</xref>,<xref rid="cit0017" ref-type="bibr">17&#8211;19</xref>]. A recent extensive network meta-analysis studied the effects of antiemetics on CINV prevention to rank antiemetic treatments according to efficacy and safety [<xref rid="cit0020" ref-type="bibr">20</xref>]. However, inconclusive evidence and outcomes did not suggest the superiority of one of the many NK<sub>1</sub> RA-based regimens (including some not marketed) over another for patients receiving HEC. Notably, this meta-analysis lacked two recently published head-to-head comparative studies [<xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0019" ref-type="bibr">19</xref>]. Without sufficient data to justify the recommended use of one NK<sub>1</sub> RA over the others, antiemetic guidelines regard all NK<sub>1</sub> RAs as clinically equivalent allowing them to be used interchangeably [<xref rid="cit0005" ref-type="bibr">5&#8211;7</xref>].</p><p>A pooled analysis of data from three cisplatin registration studies assessed the comparative efficacy of single-dose oral NEPA versus a 3-day aprepitant regimen [<xref rid="cit0021" ref-type="bibr">21</xref>]. In this analysis, response rates generally favored NEPA during the delayed (&#8201;&gt;&#8201;24&#8211;120&#8201;h) and overall (0&#8211;120&#8201;h) phases post-chemotherapy. NEPA demonstrated a significantly higher complete response (no emesis and no rescue use) rate than aprepitant during the delayed phase, along with notably lower breakthrough CINV rates on individual days 3, 4, and 5. The authors suggested that NEPA may be more effective than a 3-day aprepitant regimen; it may also provide an efficient and simplified single-dose combination of an NK<sub>1</sub> RA and 5-HT<sub>3</sub> RA, improving adherence with antiemetic prophylaxis and thereby enhancing overall effectiveness [<xref rid="cit0021" ref-type="bibr">21</xref>].</p><p>In a follow-up to this pooled analysis [<xref rid="cit0021" ref-type="bibr">21</xref>], we conducted a robust individual patient data (IPD) meta-analysis based on the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) methodology to compare the efficacy of the main NK<sub>1</sub> RAs recommended by international guidelines: netupitant- or fosnetupitant- versus aprepitant- or fosaprepitant-based regimens in preventing CINV in adult patients with cancer receiving HEC (including AC) and MEC. Unlike traditional systematic reviews that rely on aggregated data, IPD meta-analyses involve obtaining and reanalyzing the original patient-level data from each study [<xref rid="cit0022" ref-type="bibr">22</xref>]. The greater power of an IPD meta-analysis to detect differential treatment effects across individual patients in randomized trials may provide valuable evidence.</p></sec><sec disp-level="1" id="s0002"><label>2.</label><title>Methods</title><p>This research was designed in accordance with the guidance in the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA [<xref rid="cit0023" ref-type="bibr">23</xref>]; and PRISMA-IPD [<xref rid="cit0024" ref-type="bibr">24</xref>] statements). This IPD meta-analysis was not prospectively registered in a public database.</p><sec disp-level="2" id="s0002-s2001"><label>2.1.</label><title>Search strategy</title><p>Searches were conducted in the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE, and EMBASE for studies published from 2003&#9472;the year of aprepitant&#8217;s approval&#9472;through 1 April 2022 (Supplementary Table S1). The reference list from the Piechotta et al. [<xref rid="cit0020" ref-type="bibr">20</xref>] network meta-analysis was also checked for additional articles. After identifying and removing duplicate records, two authors (RMN and TT) independently screened the search results for eligible articles, first based on titles and abstracts, and only on full text when study inclusion/exclusion was unclear.</p></sec><sec disp-level="2" id="s0002-s2002"><label>2.2.</label><title>Eligibility criteria</title><p>Published randomized controlled trials with head-to-head comparisons between aprepitant or fosaprepitant (in combination with any 5-HT<sub>3</sub> RA and dexamethasone) versus oral or IV NEPA (in combination with dexamethasone) were included, given only as antiemetic prophylaxis to patients with cancer receiving single-day HEC and MEC. Non-randomized trials, case reports, and observational studies were excluded; IPD meta-analyses are resource-intensive and prioritize randomized controlled trials as they offer the strongest level of clinical evidence through clean, consistent, and complete patient-level data.</p><p>Participant eligibility included adult patients (&#8805;18&#8201;years) of both sexes and all ethnicities with a confirmed diagnosis of cancer of any type and stage. Studies included either or both patients na&#239;ve and/or non-na&#239;ve to chemotherapy who were scheduled to receive at least one cycle of single-day HEC or MEC according to the Multinational Association for Supportive Care in Cancer/European Society of Medical Oncology (MASCC/ESMO) 2016 risk categories [<xref rid="cit0025" ref-type="bibr">25</xref>]. Patients with additional CINV risk factors at baseline were included. Patients at risk for radiotherapy-induced nausea and vomiting and those at risk of nausea and vomiting due to their underlying disease were excluded.</p><p>The full SAS database used for IDP-meta-analysis was obtained by merging the individual SAS datasets standardized according to Clinical Data Interchange Standards Consortium (CDISC) Analysis Data Model (ADaM) datasets. SAS ADaM datasets were created de-novo for studies in which they were not available. The minimal data required for study inclusion were anonymous patient identifiers, antineoplastic treatment, and the randomized antiemetic treatment arm.</p><p>The following information was extracted by author EB:</p><list list-type="bullet"><list-item><p>Study-level data: study design and objectives, geographical location, dates of study conduct, eligibility criteria, comparability between treatment arms, statistical analysis, and subgroup analysis.</p></list-item><list-item><p>Patient-level data: age, gender, cancer type, antineoplastic regimen (HEC, MEC)</p></list-item><list-item><p>Interventions: antiemetic agents</p></list-item><list-item><p>Outcomes: assessment of efficacy relied on reported emetic events (either vomiting and/or retching), use of rescue medication, and the severity of nausea recorded in each patient&#8217;s diary every 24&#8201;hours during the 5&#8201;days following chemotherapy administration.</p></list-item></list></sec><sec disp-level="2" id="s0002-s2003"><label>2.3.</label><title>Assessment of risk of bias</title><p>Two authors (RMN and TT) independently evaluated the study quality and risk of bias based on the criteria outlined in the guidance for conducting IPD meta-analyses of randomized controlled trials by Tierney et al. [<xref rid="cit0026" ref-type="bibr">26</xref>]. The tool assesses potential risk of bias in study selection, data availability, participant selection, performance and detection, attrition, and outcome reporting or availability. Measures undertaken to evaluate and minimize potential bias are summarized in Supplementary Table S2. Risk of Bias was also assessed through the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) which was used to compute the scores shown in the Traffic-Light graph reported in the Supplementary Figure S1.</p></sec><sec disp-level="2" id="s0002-s2004"><label>2.4.</label><title>Data analysis</title><p>Patients who received aprepitant or fosaprepitant&#9472;regardless of the 5-HT<sub>3</sub> RA used&#9472;were grouped as &#8220;aprepitant&#8221;-based regimens, while those treated with either oral and IV NEPA were categorized as receiving &#8220;NEPA&#8221;-based regimens. Efficacy analyses were conducted using combined antiemetic treatment data from cycle 1 in the intent-to-treat (ITT) population, across all emetogenic risk categories.</p><p>A secondary analysis focused on a subset of patients for whom NK<sub>1</sub> RA regimens are recommended as antiemetic prophylaxis based on the 2023 MASCC/ESMO antiemetic guidelines [<xref rid="cit0006" ref-type="bibr">6</xref>,<xref rid="cit0008" ref-type="bibr">8</xref>]. This group included patients receiving HEC (both anthracycline-cyclophosphamide [AC] and non-AC regimens), those treated with carboplatin, or females under 50&#8201;years of age receiving oxaliplatin.</p><p>In all studies, patients recorded emetic events (vomiting and/or retching), use of rescue medication, and severity of nausea daily on diary cards. In the Hata and Matsuura studies, nausea severity was assessed on a 4-point Likert scale (none, mild, moderate, or severe), while in the other four studies, the severity of nausea was evaluated using a 100-mm horizontal visual analog scale (VAS) ranging from &#8220;no nausea&#8221; (0&#8201;mm) to &#8220;nausea as bad as it could be&#8221; (100&#8201;mm). &#8220;No significant nausea&#8221; was defined as either a nausea score of&#8201;&lt;&#8201;25&#8201;mm for studies using the VAS scale (based on research by Borjeson and colleagues [<xref rid="cit0027" ref-type="bibr">27</xref>]) or no more than mild nausea on a Likert scale.</p><p>The primary endpoint of interest was complete response during the acute (0&#8211;24&#8201;hours), delayed, and overall phases and daily during cycle 1 of chemotherapy. Daily rates of breakthrough CINV&#9472;defined as the absence of complete response, i.e., occurrence of emesis and/or used rescue antiemetic[s])&#9472;were assessed, along with incidence of no significant nausea.</p><p>We used SAS version 9.4 and the library &#8220;meta&#8221; of R software to conduct this meta-analysis of individual patient data collected from published clinical trial databases. We combined data for the acute, delayed, overall, and daily complete response and no significant nausea rates. A two-stage analytical approach was employed [<xref rid="cit0028" ref-type="bibr">28</xref>]. In the first stage, each individual trial (1<sup>st</sup> step) was analyzed separately using a log-binomial model [<xref rid="cit0029" ref-type="bibr">29</xref>] to estimate risk ratios (RRs) and corresponding variances. In the second stage, these trial-specific estimates were pooled (2<sup>nd</sup> step) using a weighted average method, implemented using SAS Mixed Procedure [<xref rid="cit0030" ref-type="bibr">30</xref>]. We used the fixed-effects model variant to combine risk ratios across studies and estimate the pooled RR with associated two-tailed 95% confidence intervals (95% CI) and two-tailed p-values.</p><p>Whenever feasible, missing data in the SAS ADaM datasets were imputed using the Missing Value Treated as Failure (MVTF) method.</p><p>Heterogeneity across studies was mainly explored performing heterogeneity test (Cochran&#8217;s Q Test) and computing heterogeneity indexes (Between-Study variation and Inconsistency Index) for the primary endpoints of interest (Supplementary Table S3). In addition, conventional Forest plots (Supplementary Figures S2) reporting the results for each study on one plot together with fixed and random effects model estimates together with Galbraith plots (Supplementary Figures S3) were used to visualize any potential heterogeneity and to perform additional sensitivity analyses (random effects model).</p><p>Leave-one-out meta-analysis (also called Influential analysis), which involves performing a meta-analysis on each subset of the randomized trials obtained by leaving out exactly one study, was carried out for each of the primary endpoints of interest (Supplementary Figures S4). This sensitivity analysis shows how each individual study affects the overall estimate of the rest of the studies providing useful information about heterogeneity, robustness of the synthesized results and in general certainty (or confidence) in the body of evidence for the assessed outcomes.</p></sec></sec><sec disp-level="1" id="s0003"><label>3.</label><title>Results</title><p>A total of 204 articles were identified through the database search. After removing duplicates (n&#8201;=&#8201;77) and excluding articles for other reasons (e.g., incomplete articles; n&#8201;=&#8201;66), 61 articles were screened for eligibility (<xref rid="f0001" ref-type="fig">Figure 1</xref>). Of these, 54 were excluded, resulting in six studies (represented by seven publications) included in this IPD meta-analysis (<xref rid="f0001" ref-type="fig">Figure 1</xref>) [<xref rid="cit0017" ref-type="bibr">17&#8211;19</xref>,<xref rid="cit0031" ref-type="bibr">31&#8211;34</xref>].
<fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>PRISMA flow diagram.</p></caption><graphic content-type="black-white" position="float" orientation="portrait" xlink:href="IFON_A_2542108_F0001_B.jpg"/></fig></p><p>All six were high-quality randomized studies, five of which were blinded [<xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0033" ref-type="bibr">33</xref>,<xref rid="cit0034" ref-type="bibr">34</xref>] and one was an open-label study conducted across 30 centers in France [<xref rid="cit0019" ref-type="bibr">19</xref>] (<xref rid="t0001" ref-type="table">Table 1</xref>). Four studies enrolled patients receiving HEC [<xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0033" ref-type="bibr">33</xref>], two included those receiving AC-containing regimens [<xref rid="cit0019" ref-type="bibr">19</xref>,<xref rid="cit0034" ref-type="bibr">34</xref>], and two included patients receiving MEC [<xref rid="cit0019" ref-type="bibr">19</xref>,<xref rid="cit0031" ref-type="bibr">31</xref>]. All the NK<sub>1</sub> RAs and 5HT<sub>3</sub> RAs had been used according to the approved dosages (<xref rid="t0001" ref-type="table">Table 1</xref>). Oral NEPA was administered in four studies as a single fixed dose compared with oral aprepitant administered for three consecutive days. Intravenous fosnetupitant plus IV palonosetron was compared with IV fosaprepitant plus IV palonosetron in the other two studies, with both regimens given on Day 1 (<xref rid="t0001" ref-type="table">Table 1</xref>).<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Key features of included studies.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Study/Primary Publication</th><th align="center" colspan="1" rowspan="1">Study Type</th><th align="center" char="." colspan="1" rowspan="1">N</th><th align="center" colspan="1" rowspan="1">Location</th><th align="center" colspan="1" rowspan="1">Emetogenicity of Most Common Chemotherapy</th><th align="center" colspan="1" rowspan="1">Most Common Cancer Types</th><th align="center" colspan="1" rowspan="1">Antiemetic Study Arms</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Hesketh et al. [<xref rid="cit0033" ref-type="bibr">33</xref>]</td><td align="left" colspan="1" rowspan="1">R, MC, DB</td><td align="char" char="." colspan="1" rowspan="1">694</td><td align="left" colspan="1" rowspan="1">Russia, Ukraine</td><td align="left" colspan="1" rowspan="1">HEC: cisplatin</td><td align="left" colspan="1" rowspan="1">Lung, Head &amp; Neck, Ovarian, Other Urogenital</td><td align="left" colspan="1" rowspan="1">Oral NETU (100, 200, and 300&#8201;mg)&#8201;+&#8201;oral PALO 0.50&#8201;mg on Day 1&#8201;+&#8201;DEX (Days 1&#8211;4)<break/>Vs.<break/>Oral PALO 0.50&#8201;mg on Day 1&#8201;+&#8201;DEX (Days 1&#8211;4)<break/>Vs.<break/>Oral APR (125&#8201;mg Day 1, 80&#8201;mg Days 2&#8211;3)&#8201;+&#8201;IV ondansetron (32&#8201;mg Day 1)&#8201;+&#8201;DEX (Days 1&#8211;4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Gralla et al. [<xref rid="cit0031" ref-type="bibr">31</xref>]</td><td align="left" colspan="1" rowspan="1">R, MC, DB</td><td align="char" char="." colspan="1" rowspan="1">413</td><td align="left" colspan="1" rowspan="1">Bulgaria, Czech Republic, Germany, Hungary, India, Poland, Russia, Serbia, Ukraine, United States</td><td align="left" colspan="1" rowspan="1">HEC: cisplatin<break/>MEC: carboplatin, oxaliplatin, doxorubicin</td><td align="left" colspan="1" rowspan="1">Lung, Ovarian, Colon, Head &amp; Neck</td><td align="left" colspan="1" rowspan="1">Oral NEPA (NETU 300&#8201;+&#8201;PALO 0.50&#8201;mg) on Day 1&#8201;+&#8201;DEX (Days 1&#8211;4 for HEC, Day 1 for MEC)<break/>Vs.<break/>Oral APR (125&#8201;mg Day 1, 80&#8201;mg Days 2&#8211;3)&#8201;+&#8201;oral PALO 0.50&#8201;mg Day 1&#8201;+&#8201;DEX (Days 1&#8211;4 for HEC, Day 1 for MEC)</td></tr><tr><td align="left" colspan="1" rowspan="1">Zhang et al. [<xref rid="cit0017" ref-type="bibr">17</xref>]</td><td align="left" colspan="1" rowspan="1">R, MC, DB</td><td align="char" char="." colspan="1" rowspan="1">828</td><td align="left" colspan="1" rowspan="1">China, Taiwan, Thailand, Korea</td><td align="left" colspan="1" rowspan="1">HEC: cisplatin</td><td align="left" colspan="1" rowspan="1">Lung, Head &amp; Neck</td><td align="left" colspan="1" rowspan="1">Oral NEPA (NETU 300&#8201;+&#8201;PALO 0.50&#8201;mg) on Day 1&#8201;+&#8201;DEX (Days 1&#8211;4)<break/>Vs.<break/>Oral APR (125&#8201;mg Day 1, 80&#8201;mg Days 2&#8211;3)&#8201;+&#8201;IV granisetron 3&#8201;mg Day 1&#8201;+&#8201;DEX (Days 1&#8211;4 for HEC)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hata et al. [<xref rid="cit0018" ref-type="bibr">18</xref>]</td><td align="left" colspan="1" rowspan="1">R, MC, DB</td><td align="char" char="." colspan="1" rowspan="1">785</td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">HEC: cisplatin</td><td align="left" colspan="1" rowspan="1">Lung, Esophagus, Head &amp; Neck</td><td align="left" colspan="1" rowspan="1">IV Fosnetupitant (235&#8201;mg)&#8201;+&#8201;IV PALO 0.75&#8201;mg on Day 1&#8201;+&#8201;DEX (Days 1&#8211;4)<break/>Vs.<break/>IV Fosaprepitant (150&#8201;mg)&#8201;+&#8201;IV PALO 0.75&#8201;mg on Day 1&#8201;+&#8201;DEX (Days 1&#8211;4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Zelek et al. [<xref rid="cit0019" ref-type="bibr">19</xref>]</td><td align="left" colspan="1" rowspan="1">R, MC, OL</td><td align="char" char="." colspan="1" rowspan="1">373</td><td align="left" colspan="1" rowspan="1">France</td><td align="left" colspan="1" rowspan="1">HEC: AC<break/>MEC: oxaliplatin, carboplatin, irinotecan</td><td align="left" colspan="1" rowspan="1">Breast, Gastric Lung</td><td align="left" colspan="1" rowspan="1">Oral NEPA (NETU 300&#8201;+&#8201;PALO 0.50&#8201;mg) on Day 1&#8201;+&#8201;DEX (Days 1&#8211;4)<break/>Vs.<break/>Oral APR (125&#8201;mg Day 1, 80&#8201;mg Days 2&#8211;3)&#8201;+&#8201;IV ondansetron 8&#8201;mg Day 1&#8201;+&#8201;DEX (Days 1&#8211;4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Matsuura et al. [<xref rid="cit0034" ref-type="bibr">34</xref>]</td><td align="left" colspan="1" rowspan="1">R, MC, DB</td><td align="char" char="." colspan="1" rowspan="1">102</td><td align="left" colspan="1" rowspan="1">Japan</td><td align="left" colspan="1" rowspan="1">HEC: AC</td><td align="left" colspan="1" rowspan="1">Breast</td><td align="left" colspan="1" rowspan="1">IV Fosnetupitant (235&#8201;mg)&#8201;+&#8201;IV PALO 0.75&#8201;mg on Day 1&#8201;+&#8201;DEX (Day 1 only)<break/>Vs.<break/>IV Fosaprepitant (150&#8201;mg)&#8201;+&#8201;IV PALO 0.75&#8201;mg on Day 1&#8201;+&#8201;DEX (Day 1 only)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Abbreviations</bold>: <bold>R</bold>: randomized<bold>; MC</bold>: multicenter; <bold>DB</bold>: double-blind; <bold>OL</bold>: open label; <bold>HEC</bold>: highly emetogenic chemotherapy<bold>; MEC</bold>: moderately emetogenic chemotherapy<bold>; AC</bold>: anthracycline cyclophosphamide<bold>; APR</bold>: aprepitant; <bold>DEX</bold>: dexamethasone; <bold>NETU</bold>: netupitant; <bold>PALO</bold>: palonosetron; <bold>IV</bold>: intravenous; <bold>NEPA</bold>: netupitant/palonosetron; <bold>OND</bold>: ondansetron; <bold>mg</bold>: milligrams.</p></fn></table-wrap-foot></table-wrap></p><p>A total of 2,767 patients were included in this IPD meta-analysis. The majority were male with a mean age of 58&#8201;years. Most patients (81%) received HEC and approximately two-thirds (68%) were treated with the oral formulations of NEPA and aprepitant (<xref rid="t0002" ref-type="table">Table 2</xref>).<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>Patient demographics and chemotherapy (all patients).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">NEPA (n&#8201;=&#8201;1486)</th><th align="center" colspan="1" rowspan="1">Aprepitant (n&#8201;=&#8201;1281)</th><th align="center" colspan="1" rowspan="1">All Patients<break/>(N&#8201;=&#8201;2767)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><bold>Age (mean&#8201;&#177;&#8201;SD, years)</bold></td><td align="center" colspan="1" rowspan="1">58.5 (&#177;10.7)</td><td align="center" colspan="1" rowspan="1">58.3 (&#177;11.0)</td><td align="center" colspan="1" rowspan="1">58.4 (&#177;10.9)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Sex</bold></td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="center" colspan="1" rowspan="1">596 (40.1%)</td><td align="center" colspan="1" rowspan="1">503 (39.3%)</td><td align="center" colspan="1" rowspan="1">1099 (39.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="center" colspan="1" rowspan="1">890 (59.9%)</td><td align="center" colspan="1" rowspan="1">778 (60.7%)</td><td align="center" colspan="1" rowspan="1">1668 (60.3%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Most Common Chemotherapy Agents</bold></td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Highly Emetogenic<break/><italic toggle="yes">Cisplatin</italic><break/><italic toggle="yes">Anthracycline Cyclophosphamide</italic></td><td align="center" colspan="1" rowspan="1">1142 (76.9%)<break/>1011 (68.0%)<break/>129 (8.7%)</td><td align="center" colspan="1" rowspan="1">1102 (86.0%)<break/>966 (75.4%)<break/>133 (10.4%)</td><td align="center" colspan="1" rowspan="1">2244 (81.1%)<break/>1977 (71.4%)<break/>262 (9.5%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Moderately Emetogenic*<break/><italic toggle="yes">Carboplatin</italic><break/><italic toggle="yes">Oxaliplatin</italic><break/><italic toggle="yes">Irinotecan</italic><break/><italic toggle="yes">Doxorubicin</italic></td><td align="center" colspan="1" rowspan="1">344 (23.1%)<break/>191 (12.6%)<break/>103 (6.9%)<break/>22 (1.5%)<break/>33 (2.2%)</td><td align="center" colspan="1" rowspan="1">179 (14.0%)<break/>86 (6.7%)<break/>77 (6.0%)<break/>20 (1.6%)<break/>7 (0.5%)</td><td align="center" colspan="1" rowspan="1">523 (18.9%)<break/>277 (10.0%)<break/>180 (6.5%)<break/>42 (1.5%)<break/>40 (1.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Chemotherapy Na&#239;ve</bold><break/><bold>Chemotherapy Non-na&#239;ve</bold></td><td align="center" colspan="1" rowspan="1">1481 (99.7%)<break/>5 (0.3%)</td><td align="center" colspan="1" rowspan="1">1281 (100%)<break/>0</td><td align="center" colspan="1" rowspan="1">2762 (99.8%)<break/>5 (0.2%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Most Common Cancer Types</bold><break/>Lung<break/>Breast<break/>Head &amp; Neck<break/>Ovarian<break/>Colon/Colorectal<break/>Other</td><td align="center" colspan="1" rowspan="1">734 (49.4%)<break/>176 (11.8%)<break/>168 (11.3%)<break/>63 (4.2%)<break/>66 (4.4%)<break/>279 (18.8%)</td><td align="center" colspan="1" rowspan="1">620 (48.4%)<break/>153 (11.9%)<break/>142 (11.1%)<break/>51 (4.0%)<break/>38 (3.0%)<break/>277 (21.6%)</td><td align="center" colspan="1" rowspan="1">1354 (48.9%)<break/>329 (12.0%)<break/>310 (11.2%)<break/>114 (4.1%)<break/>104 (3.8%)<break/>556 (20.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Antiemetic Regimen</bold></td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">IV NEPA (fosnetupitant/palonosetron)</td><td align="center" colspan="1" rowspan="1">443 (29.8%)</td><td align="center" colspan="1" rowspan="1">0</td><td align="center" colspan="1" rowspan="1">443 (16.1%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Oral NEPA (netupitant/palonosetron)</td><td align="center" colspan="1" rowspan="1">1043 (70.2%)</td><td align="center" colspan="1" rowspan="1">0</td><td align="center" colspan="1" rowspan="1">1043 (37.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Fosaprepitant (IV)</td><td align="center" colspan="1" rowspan="1">0</td><td align="center" colspan="1" rowspan="1">442 (34.5%)</td><td align="center" colspan="1" rowspan="1">442 (16.0%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Aprepitant (oral)</td><td align="center" colspan="1" rowspan="1">0</td><td align="center" colspan="1" rowspan="1">839 (65.5%)</td><td align="center" colspan="1" rowspan="1">839 (30.3%)</td></tr></tbody></table><table-wrap-foot><fn id="tfn0002"><p>*Patients who received more than one MEC agent are included with each agent.</p></fn></table-wrap-foot></table-wrap></p><sec disp-level="2" id="s0003-s2001"><label>3.1.</label><title>Efficacy outcomes (all patients)</title><p>The IPD meta-analysis demonstrated comparable efficacy between NEPA and aprepitant in the acute phase. However, NEPA was associated with statistically significantly higher complete response rates during both the delayed and overall phases post-chemotherapy (Risk Ratio&#8201;&gt;&#8201;1) (<xref rid="t0003" ref-type="table">Table 3</xref>). This advantage was further reflected in lower daily rates of breakthrough CINV on Days 3, 4, and 5, with patients receiving NEPA experiencing significantly fewer recurrent symptoms than those treated with aprepitant (<xref rid="t0003" ref-type="table">Table 3</xref> and <xref rid="f0002a" ref-type="fig">Figure 2a</xref>).
<fig position="float" id="f0002a" fig-type="figure" orientation="portrait"><label>Figure 2a.</label><caption><p>Crude pooled daily incidence of breakthrough emesis and/or use of rescue medication (all patients in the intent-to-treat population).</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="IFON_A_2542108_F0002a_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="IFON_A_2542108_F0002a_PB.jpg"/></alternatives><attrib>This figure shows the proportion of patients who experienced breakthrough emesis and/or used rescue medication each day despite receiving antiemetic prophylaxis.</attrib></fig><table-wrap position="float" id="t0003" orientation="portrait"><label>Table 3.</label><caption><p>Crude pooled proportions of patients experiencing complete response and no significant nausea. IPD meta-analysis estimates of risk ratios with two-tailed 95% CI and P-values (all patients in the intent-to-treat population).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Time Point</th><th align="center" colspan="1" rowspan="1">NEPA (n&#8201;=&#8201;1486)</th><th align="center" colspan="1" rowspan="1">Aprepitant (n&#8201;=&#8201;1281)</th><th align="center" char="." colspan="1" rowspan="1">Risk Ratio</th><th align="center" char="." colspan="1" rowspan="1">Two-Tailed 95% CI</th><th colspan="2" align="center" rowspan="1">P-value</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1"><bold>Complete Response</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Acute (0&#8211;24&#8201;h)</td><td align="center" colspan="1" rowspan="1">1314 (88.4%)</td><td align="center" colspan="1" rowspan="1">1124 (87.7%)</td><td align="char" char="." colspan="1" rowspan="1">1.008</td><td colspan="2" align="char" char="." rowspan="1">(0.985, 1.031)</td><td align="left" colspan="1" rowspan="1">0.4865</td></tr><tr><td align="left" colspan="1" rowspan="1">Day 2 (25&#8211;48&#8201;h)</td><td align="center" colspan="1" rowspan="1">1285 (86.5%)</td><td align="center" colspan="1" rowspan="1">1091 (85.2%)</td><td align="char" char="." colspan="1" rowspan="1">1.006</td><td colspan="2" align="char" char="." rowspan="1">(0.979, 1.035)</td><td align="left" colspan="1" rowspan="1">0.6560</td></tr><tr><td align="left" colspan="1" rowspan="1">Day 3 (49&#8211;72&#8201;h)</td><td align="center" colspan="1" rowspan="1">1287 (86.6%)</td><td align="center" colspan="1" rowspan="1">1069 (83.5%)</td><td align="char" char="." colspan="1" rowspan="1">1.029</td><td colspan="2" align="char" char="." rowspan="1">(1.001, 1.058)</td><td align="left" colspan="1" rowspan="1"><bold>0.0408</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Day 4 (73&#8211;96&#8201;h)</td><td align="center" colspan="1" rowspan="1">1307 (88%)</td><td align="center" colspan="1" rowspan="1">1083 (84.5%)</td><td align="char" char="." colspan="1" rowspan="1">1.037</td><td colspan="2" align="char" char="." rowspan="1">(1.010, 1.065)</td><td align="left" colspan="1" rowspan="1"><bold>0.0072</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Day 5 (97&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">1331 (89.6%)</td><td align="center" colspan="1" rowspan="1">1083 (84.5%)</td><td align="char" char="." colspan="1" rowspan="1">1.057</td><td colspan="2" align="char" char="." rowspan="1">(1.028, 1.087)</td><td align="left" colspan="1" rowspan="1"><bold>0.0001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Delayed (&#8201;&gt;&#8201;24&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">1159 (78%)</td><td align="center" colspan="1" rowspan="1">931 (72.7%)</td><td align="char" char="." colspan="1" rowspan="1">1.054</td><td colspan="2" align="char" char="." rowspan="1">(1.011, 1.098)</td><td align="left" colspan="1" rowspan="1"><bold>0.0125</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Overall (0&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">1114 (75%)</td><td align="center" colspan="1" rowspan="1">900 (70.3%)</td><td align="char" char="." colspan="1" rowspan="1">1.050</td><td colspan="2" align="char" char="." rowspan="1">(1.005, 1.097)</td><td align="left" colspan="1" rowspan="1"><bold>0.0300</bold></td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>No Significant Nausea</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Acute (0&#8211;24&#8201;h)</td><td align="center" colspan="1" rowspan="1">1332 (89.6%)</td><td align="center" colspan="1" rowspan="1">1139 (88.9%)</td><td align="char" char="." colspan="1" rowspan="1">1.007</td><td colspan="2" align="char" char="." rowspan="1">(0.978, 1.036)</td><td align="left" colspan="1" rowspan="1">0.6551</td></tr><tr><td align="left" colspan="1" rowspan="1">Day 2 (25&#8211;48&#8201;h)</td><td align="center" colspan="1" rowspan="1">1301 (87.6%)</td><td align="center" colspan="1" rowspan="1">1102 (86%)</td><td align="char" char="." colspan="1" rowspan="1">1.013</td><td colspan="2" align="char" char="." rowspan="1">(0.986, 1.040)</td><td align="left" colspan="1" rowspan="1">0.3590</td></tr><tr><td align="left" colspan="1" rowspan="1">Day 3 (49&#8211;72&#8201;h)</td><td align="center" colspan="1" rowspan="1">1306 (87.9%)</td><td align="center" colspan="1" rowspan="1">1074 (83.8%)</td><td align="char" char="." colspan="1" rowspan="1">1.039</td><td colspan="2" align="char" char="." rowspan="1">(1.010, 1.069)</td><td align="left" colspan="1" rowspan="1"><bold>0.0074</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Day 4 (73&#8211;96&#8201;h)</td><td align="center" colspan="1" rowspan="1">1327 (89.3%)</td><td align="center" colspan="1" rowspan="1">1098 (85.7%)</td><td align="char" char="." colspan="1" rowspan="1">1.044</td><td colspan="2" align="char" char="." rowspan="1">(1.017, 1.072)</td><td align="left" colspan="1" rowspan="1"><bold>0.0015</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Day 5 (97&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">1326 (89.2%)</td><td align="center" colspan="1" rowspan="1">1096 (85.6%)</td><td align="char" char="." colspan="1" rowspan="1">1.037</td><td colspan="2" align="char" char="." rowspan="1">(1.008, 1.066)</td><td align="left" colspan="1" rowspan="1"><bold>0.0118</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Delayed<break/>(&#8201;&gt;&#8201;24&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">1198 (80.6%)</td><td align="center" colspan="1" rowspan="1">973 (76%)</td><td align="char" char="." colspan="1" rowspan="1">1.046</td><td colspan="2" align="char" char="." rowspan="1">(1.008, 1.086)</td><td align="left" colspan="1" rowspan="1"><bold>0.0189</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Overall<break/>(0&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">1160 (78.1%)</td><td align="center" colspan="1" rowspan="1">939 (73.3%)</td><td align="char" char="." colspan="1" rowspan="1">1.047</td><td colspan="2" align="char" char="." rowspan="1">(1.006, 1.090)</td><td align="left" colspan="1" rowspan="1"><bold>0.0240</bold></td></tr></tbody></table></table-wrap></p><p>Similar findings were observed for the endpoint of no significant nausea, with significantly higher rates estimated for NEPA compared to aprepitant during the delayed and overall phases, as well as on individual Days 3, 4, and 5 (<xref rid="t0003" ref-type="table">Table 3</xref> and <xref rid="f0002a" ref-type="fig">Figure 2b</xref>).
<fig position="float" id="f0002b" fig-type="figure" orientation="portrait"><label>Figure 2b.</label><caption><p>Crude pooled daily incidence of breakthrough significant nausea (all patients in the intent-to-treat population).</p></caption><alternatives><graphic content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="IFON_A_2542108_F0002b_OC.jpg"/><graphic content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="IFON_A_2542108_F0002b_PB.jpg"/></alternatives><attrib>This figure shows the proportion of patients who experienced breakthrough nausea (more than mild) each day despite receiving antiemetic prophylaxis.</attrib></fig></p><p>Sensitivity IPD meta-analyses performed with random effect models (Supplementary Figures S2) and/or parameterized with odds ratios (results not shown) led to the same conclusion: treatment with NEPA significantly increased the rate of complete response and no significant nausea compared to treatment with aprepitant/fosaprepitant. This increase was evident starting from the third day after chemotherapy and was confirmed in the analyses of the delayed and overall phases.</p></sec><sec disp-level="2" id="s0003-s2002"><label>3.2.</label><title>Guideline-based subset</title><sec disp-level="3" id="s0003-s2002-s3001"><label>3.2.1.</label><title>Patients receiving HEC, carboplatin, and oxaliplatin/female/&lt;&#8201;50&#8201;years</title><p>There were 2,532 patients in the subset for whom an NK<sub>1</sub> RA is recommended as primary prophylaxis according to guideline recommendations [<xref rid="cit0008" ref-type="bibr">8</xref>]. In this subgroup, consistent with findings from the overall population, the IPD meta-analysis estimated significantly higher complete response rates for NEPA compared to aprepitant during the delayed and overall phases, as well as on individual Days 3, 4, and 5 (<xref rid="t0004" ref-type="table">Table 4</xref>). Similarly, significantly higher rates of no significant nausea were estimated for NEPA during the delayed and overall phases and on Days 3&#8211;5.<table-wrap position="float" id="t0004" orientation="portrait"><label>Table 4.</label><caption><p>Crude pooled proportions of patients experiencing complete response and no significant nausea. IPD meta-analysis estimates of risk ratios with two-tailed 95% CI and P-values. (subset of patients receiving highly emetogenic chemotherapy, carboplatin and oxaliplatin/female/&#8201;&lt;&#8201;50&#8201;years).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="char" char="." span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Time Point</th><th align="center" colspan="1" rowspan="1">NEPA (n&#8201;=&#8201;1486)</th><th align="center" colspan="1" rowspan="1">Aprepitant (n&#8201;=&#8201;1281)</th><th align="center" char="." colspan="1" rowspan="1">Risk Ratio</th><th align="center" char="." colspan="1" rowspan="1">Two-Tailed 95% CI</th><th colspan="2" align="center" rowspan="1">P-value</th></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1"><bold>Complete Response</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Acute (0&#8211;24&#8201;h)</td><td align="center" colspan="1" rowspan="1">1185 (88.5%)</td><td align="center" colspan="1" rowspan="1">1053 (88.3%)</td><td align="char" char="." colspan="1" rowspan="1">1.011</td><td colspan="2" align="char" char="." rowspan="1">(0.987, 1.035)</td><td align="left" colspan="1" rowspan="1">0.3875</td></tr><tr><td align="left" colspan="1" rowspan="1">Day 2 (25&#8211;48&#8201;h)</td><td align="center" colspan="1" rowspan="1">1151 (86.0%)</td><td align="center" colspan="1" rowspan="1">1015 (85.1%)</td><td align="char" char="." colspan="1" rowspan="1">1.006</td><td colspan="2" align="char" char="." rowspan="1">(0.977, 1.035)</td><td align="left" colspan="1" rowspan="1">0.7081</td></tr><tr><td align="left" colspan="1" rowspan="1">Day 3 (49&#8211;72&#8201;h)</td><td align="center" colspan="1" rowspan="1">1160 (86.6%)</td><td align="center" colspan="1" rowspan="1">998 (83.7%)</td><td align="char" char="." colspan="1" rowspan="1">1.030</td><td colspan="2" align="char" char="." rowspan="1">(1.001, 1.060)</td><td align="left" colspan="1" rowspan="1"><bold>0.0418</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Day 4 (73&#8211;96&#8201;h)</td><td align="center" colspan="1" rowspan="1">1182 (88.3%)</td><td align="center" colspan="1" rowspan="1">1013 (84.9%)</td><td align="char" char="." colspan="1" rowspan="1">1.037</td><td colspan="2" align="char" char="." rowspan="1">(1.009, 1.065)</td><td align="left" colspan="1" rowspan="1"><bold>0.0090</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Day 5 (97&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">1205 (90.0%)</td><td align="center" colspan="1" rowspan="1">1006 (84.3%)</td><td align="char" char="." colspan="1" rowspan="1">1.063</td><td colspan="2" align="char" char="." rowspan="1">(1.033, 1.094)</td><td align="left" colspan="1" rowspan="1"><bold>&#8201;&lt;&#8201;.0001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Delayed<break/>(&#8201;&gt;&#8201;24&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">1039 (77.6%)</td><td align="center" colspan="1" rowspan="1">870 (72.9%)</td><td align="char" char="." colspan="1" rowspan="1">1.051</td><td colspan="2" align="char" char="." rowspan="1">(1.007, 1.096)</td><td align="left" colspan="1" rowspan="1"><bold>0.0220</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Overall<break/>(0&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">998 (74.5%)</td><td align="center" colspan="1" rowspan="1">842 (70.6%)</td><td align="char" char="." colspan="1" rowspan="1">1.047</td><td colspan="2" align="char" char="." rowspan="1">(1.001, 1.096)</td><td align="left" colspan="1" rowspan="1"><bold>0.0469</bold></td></tr><tr><td colspan="7" align="left" rowspan="1"><bold>No Significant Nausea</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Acute (0&#8211;24&#8201;h)</td><td align="center" colspan="1" rowspan="1">1199 (89.5%)</td><td align="center" colspan="1" rowspan="1">1066 (89.4%)</td><td align="char" char="." colspan="1" rowspan="1">1.007</td><td colspan="2" align="char" char="." rowspan="1">(0.978, 1.037)</td><td align="left" colspan="1" rowspan="1">0.6490</td></tr><tr><td align="left" colspan="1" rowspan="1">Day 2 (25&#8211;48&#8201;h)</td><td align="center" colspan="1" rowspan="1">1171 (87.5%)</td><td align="center" colspan="1" rowspan="1">1025 (85.9%)</td><td align="char" char="." colspan="1" rowspan="1">1.017</td><td colspan="2" align="char" char="." rowspan="1">(0.989, 1.045)</td><td align="left" colspan="1" rowspan="1">0.2422</td></tr><tr><td align="left" colspan="1" rowspan="1">Day 3 (49&#8211;72&#8201;h)</td><td align="center" colspan="1" rowspan="1">1180 (88.1%)</td><td align="center" colspan="1" rowspan="1">1000 (83.8%)</td><td align="char" char="." colspan="1" rowspan="1">1.043</td><td colspan="2" align="char" char="." rowspan="1">(1.013, 1.074)</td><td align="left" colspan="1" rowspan="1"><bold>0.0050</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Day 4 (73&#8211;96&#8201;h)</td><td align="center" colspan="1" rowspan="1">1198 (89.5%)</td><td align="center" colspan="1" rowspan="1">1021 (85.6%)</td><td align="char" char="." colspan="1" rowspan="1">1.047</td><td colspan="2" align="char" char="." rowspan="1">(1.019, 1.076)</td><td align="left" colspan="1" rowspan="1"><bold>0.0010</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Day 5 (97&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">1193 (89.1%)</td><td align="center" colspan="1" rowspan="1">1019 (85.4%)</td><td align="char" char="." colspan="1" rowspan="1">1.039</td><td colspan="2" align="char" char="." rowspan="1">(1.009, 1.069)</td><td align="left" colspan="1" rowspan="1"><bold>0.0114</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Delayed<break/>(&#8201;&gt;&#8201;24&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">1080 (80.7%)</td><td align="center" colspan="1" rowspan="1">906 (75.9%)</td><td align="char" char="." colspan="1" rowspan="1">1.050</td><td colspan="2" align="char" char="." rowspan="1">(1.009, 1.091)</td><td align="left" colspan="1" rowspan="1"><bold>0.0155</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Overall<break/>(0&#8211;120&#8201;h)</td><td align="center" colspan="1" rowspan="1">1045 (78.0%)</td><td align="center" colspan="1" rowspan="1">878 (73.6%)</td><td align="char" char="." colspan="1" rowspan="1">1.049</td><td colspan="2" align="char" char="." rowspan="1">(1.006, 1.094)</td><td align="left" colspan="1" rowspan="1"><bold>0.0245</bold></td></tr></tbody></table></table-wrap></p></sec></sec></sec><sec disp-level="1" id="s0004"><label>4.</label><title>Discussion</title><p>Compared to a rigorously controlled comparative clinical trial, meta-analyses may be criticized due to potential issues of poor quality of included studies, heterogeneity among studies, and publication bias [<xref rid="cit0035" ref-type="bibr">35</xref>]. However, the vast amount of medical information and variability between individual studies can make it challenging for healthcare providers to make optimal clinical decisions. Meta&#8208;analyses, which aggregate and quantitatively synthesize results from eligible studies, have become increasingly important for guiding clinical practice. Individual patient data meta-analyses are widely regarded as the gold standard for meta-analyses. This method involves examining patient-specific data, rather than relying on summarized outcomes, thereby aiding in the mitigation of heterogeneity [<xref rid="cit0036" ref-type="bibr">36</xref>].</p><p>In our IPD meta-analysis, NEPA-based regimens were statistically significantly better at preventing CINV than aprepitant/fosaprepitant-based regimens during the delayed and overall phases post-chemotherapy. Notably, the differences were most prominent during the later days, specifically Days 3&#8211;5. Consistent results were seen for the prevention of significant nausea, a consistently reported unmet need for patients undergoing emetogenic chemotherapy [<xref rid="cit0037" ref-type="bibr">37</xref>,<xref rid="cit0038" ref-type="bibr">38</xref>]. As only one of the studies had evaluated the impact of nausea on daily functioning, this was not able to be included as an endpoint; however, it is noteworthy that in the Zhang study, a greater proportion of patients treated with NEPA reported no impact on daily living due to nausea during the delayed phase compared to those receiving aprepitant, as measured by the Functional Living Index-Emesis (FLIE) questionnaire [<xref rid="cit0017" ref-type="bibr">17</xref>].</p><p>Comparable results were seen for both efficacy endpoints in the large subset of patients who received HEC and selective MEC agents (plus emetic risk factors), aligning with the guideline recommendations for whom an NK<sub>1</sub> RA-containing regimen is warranted.</p><p>These IPD meta-analysis findings reinforce the previously published pooled analysis by Navari et al., which evaluated three NEPA registration trials in patients receiving HEC and found NEPA to be more effective than an aprepitant regimen in preventing CINV during the delayed phase and on Days 3&#8211;5 post-cisplatin. However, this larger IPD meta-analysis includes three additional studies and a broader, more diverse patient population&#9472;encompassing those receiving AC-based HEC, and various MEC regimens, including carboplatin and oxaliplatin&#9472;chemotherapy types for which current guidelines recommend the use of an NK<sub>1</sub> RA. One potential limitation of the present analysis is the inclusion of an open-label study [<xref rid="cit0019" ref-type="bibr">19</xref>]. Notably, this analysis includes over 800 patients treated with IV formulations of NEPA and aprepitant, enhancing the relevance of these findings to real-world clinical use across both oral and IV regimens. In both analyses, the greatest incremental difference in complete response was observed on Day 5 suggesting NEPA&#8217;s benefit may extend beyond the delayed phase [<xref rid="cit0021" ref-type="bibr">21</xref>].</p><p>This observed differentiation could be attributed to underlying pharmacological differences between NEPA and aprepitant. The long elimination half-lives of netupitant and palonosetron likely contribute to its long-lasting CINV protection. The half-life of oral netupitant is 88&#8201;hours [<xref rid="cit0010" ref-type="bibr">10</xref>] compared with 9&#8211;13&#8201;h for aprepitant [<xref rid="cit0011" ref-type="bibr">11</xref>]. Recent pharmacokinetic/pharmacodynamic modeling revealed extended NK<sub>1</sub> receptor occupancy (RO) of netupitant in the striatum region of the brain relative to aprepitant [<xref rid="cit0039" ref-type="bibr">39</xref>]. The RO patterns for netupitant and aprepitant were quite distinct, with a persistent and gradual decline of percent NK<sub>1</sub> RO for 20&#8201;days following a single dose of netupitant compared with a rapid decline in RO for 3-day aprepitant after 6&#8201;days. The NK<sub>1</sub> RO reached 90% by 3&#8201;h for both agents. RO remained high up to 120&#8201;h (day 5) for both netupitant and aprepitant but then dropped substantially for aprepitant and gradually declined for netupitant. At 168&#8201;h (day 7), the RO was 70% for netupitant and 39% for aprepitant. The RO for netupitant and aprepitant, respectively, at 192&#8201;h (day 8), 240&#8201;h (day 10), and 480&#8201;h (day 20) was 67% vs 19%, 60% vs 3%, and 22% vs 0% [<xref rid="cit0039" ref-type="bibr">39</xref>].</p><p>There is also pharmacologic support for a synergistic interaction between netupitant and palonosetron. When administered together, these agents produce greater inhibition of substance P-induced activity at NK<sub>1</sub> receptors than when used individually [<xref rid="cit0040" ref-type="bibr">40</xref>]. Mechanistic studies further demonstrate that netupitant [<xref rid="cit0041" ref-type="bibr">41</xref>] and palonosetron [<xref rid="cit0042" ref-type="bibr">42</xref>] trigger internalization of the NK<sub>1</sub> and 5-HT<sub>3</sub> receptors, respectively. Importantly, netupitant-induced NK<sub>1</sub> receptor internalization is enhanced in the presence of palonosetron [<xref rid="cit0041" ref-type="bibr">41</xref>].</p><p>The results of this IPD analysis, combined with the pharmacological evidence, suggest that while netupitant and aprepitant are both highly effective antiemetics, NEPA may have longer-lasting benefits in preventing CINV in the later days post-chemotherapy. More recent studies with NEPA outside this IPD meta-analysis have begun assessing CINV prevention beyond 120&#8201;h. In a pooled analysis of a Phase II and Phase III study in Japan comparing fosnetupitant with fosaprepitant in patients receiving cisplatin-based HEC, there was a significantly higher complete response rate for fosnetupitant during an extended overall phase of 0&#8211;168&#8201;h [<xref rid="cit0043" ref-type="bibr">43</xref>]. In a study in France designed to evaluate the comparative efficacy of NEPA versus aprepitant in patients receiving MEC, NEPA showed significantly higher complete response rates than aprepitant during an extended overall phase up to 144&#8201;h [<xref rid="cit0044" ref-type="bibr">44</xref>]. In a single-arm, open-label phase II study in Denmark, the efficacy and safety of NEPA was evaluated in patients with cervical cancer undergoing radiotherapy and weekly cisplatin [<xref rid="cit0045" ref-type="bibr">45</xref>]. NEPA effectively prevented nausea and vomiting over an extended period of 35&#8201;days. Finally, a real-world study was recently conducted in India to assess the effectiveness and safety of intravenous NEPA in preventing CINV during a &#8220;long-delayed phase&#8221; (&#8201;&gt;&#8201;120&#8211;240&#8201;h) in patients receiving HEC and MEC [<xref rid="cit0046" ref-type="bibr">46</xref>]. NEPA was highly effective with a complete response rate of&#8201;&gt;&#8201;90% during this long-delayed phase.</p><p>Only recently has attention begun to focus on CINV persisting beyond 120&#8201;h post-chemotherapy. Chow and colleagues published a systematic review and meta-analysis aimed at reporting the prevalence of &#8220;long-delayed&#8221; CINV (i.e., that occurring&#8201;&gt;&#8201;120&#8201;h) [<xref rid="cit0038" ref-type="bibr">38</xref>]. This review highlights a persistent unmet need clinicians may not be aware of. In an extensive population of&#8201;&gt;&#8201;2,000 patients, 31% of those receiving HEC and 24% of those receiving MEC experienced long-delayed nausea; this nausea was as severe as during the delayed phase, and importantly, patients experiencing nausea and vomiting on Days 4 and 5 were deemed to be at significant risk of experiencing long-delayed CINV. This finding is particularly relevant to the results of this IPD meta-analysis, where differences were most prominent during these days when uncontrolled CINV is more likely to result in long-delayed CINV.</p><p>The therapeutic landscape in oncology is rapidly evolving with the introduction of novel targeted therapies. Emerging data on some of these therapies, such as ADCs, suggest that nausea and vomiting are not only common side effects associated with many of these agents but can last well beyond the timeframe seen with traditional chemotherapy [<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0003" ref-type="bibr">3</xref>,<xref rid="cit0047" ref-type="bibr">47</xref>]. Even Grade 1 nausea [according to the Common Terminology Criteria for Adverse Events (CTCAE) [<xref rid="cit0048" ref-type="bibr">48</xref>]], which can persist over time for several days and subsequent cycles, may lead to persistent deleterious effects on patients&#8217; quality of life [<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0003" ref-type="bibr">3</xref>,<xref rid="cit0047" ref-type="bibr">47</xref>,<xref rid="cit0049" ref-type="bibr">49</xref>,<xref rid="cit0050" ref-type="bibr">50</xref>] and poor adherence to targeted treatment if not optimally controlled. Consequently, healthcare professionals face a new challenge of monitoring and managing CINV beyond the conventional 5&#8201;days post-chemotherapy. Selecting an antiemetic regimen that offers lasting protection against CINV will be important. The longer half-life of NEPA and emerging data on NEPA&#8217;s prolonged receptor occupancy and efficacy beyond 5&#8201;days make it a promising antiemetic for preventing nausea and vomiting associated with emetogenic ADCs. Studies should be conducted in the ADC setting to evaluate the potential benefits of NEPA over aprepitant regimens, focusing on assessing the efficacy in the long-delayed phase.</p></sec><sec disp-level="1" id="s0005"><label>5.</label><title>Conclusion</title><p>The results of the current analysis suggest that NEPA regimens, which include netupitant and fosnetupitant, can potentially provide extended protection from nausea and vomiting than aprepitant regimens, making them promising options for use with new anticancer targeted therapies. Clinical studies will be beneficial in further determining the time course of nausea and vomiting associated with ADCs and evaluating the extended duration benefits of single-dose NEPA-based regimens in this setting.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM8780" position="float" content-type="local-data" orientation="portrait"><caption><title>Supplemental Material</title></caption><media xlink:href="IFON_A_2542108_SM8780.zip" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>The authors are fully responsible for all content and editorial decisions for this manuscript. This research was presented at the Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting held June 27&#8211;29 in Lille, France.</p></ack><sec disp-level="1" id="s0006"><title>Article highlights</title><p>
<list list-type="bullet" id="list_0001"><list-item><p>Currently, four classes of drugs are recommended by antiemetic guidelines as prophylaxis for chemotherapy-induced nausea and vomiting (CINV): neurokinin-1 (NK<sub>1</sub>) receptor antagonists (RAs), 5-hydroxytryptamine-3 (5-HT<sub>3</sub>) RAs, corticosteroids (mainly dexamethasone), and psychotropics (mainly olanzapine).</p></list-item><list-item><p>A three-drug combination consisting of an NK<sub>1</sub> RA, a 5-HT<sub>3</sub> RA, and dexamethasone, with or without olanzapine, is guideline-recommended for patients receiving highly emetogenic chemotherapy (HEC), including anthracycline-cyclophosphamide (AC) as well as for patients receiving carboplatin-based regimens or oxaliplatin if female and &#8804;50&#8201;years and for patients receiving moderately emetogenic chemotherapy (MEC) who have CINV risk factors, or for whom CINV was not controlled following prophylaxis with a 5-HT<sub>3</sub> RA and dexamethasone alone.</p></list-item><list-item><p>In the absence of comparative evidence demonstrating clinically meaningful differences in efficacy among NK<sub>1</sub> RAs, current antiemetic guidelines consider these agents as therapeutically similar and interchangeable.</p></list-item><list-item><p>This individual patient data (IPD) meta-analysis was designed to compare the efficacy of oral netupitant- or IV fosnetupitant- vs. oral aprepitant- or IV fosaprepitant-based regimens in preventing CINV in adult patients with cancer receiving HEC (including AC) and MEC.</p></list-item><list-item><p>This analysis combined data from six clinical studies involving 2,767 patients. Results showed that NEPA-based regimens were statistically significantly better at preventing CINV than aprepitant/fosaprepitant-based regimens during the delayed and overall phases post-chemotherapy. Notably, the differences were most prominent during the later days, specifically Days 3&#8211;5, suggesting NEPA&#8217;s benefit may continue beyond the delayed phase.</p></list-item><list-item><p>NEPA-containing regimens may be particularly promising for managing the prolonged duration of nausea and vomiting that can accompany newer targeted anticancer treatments such as antibody-drug conjugates.</p></list-item></list></p></sec><sec disp-level="1" id="s0007"><title>Author contributions</title><p><bold>Rudolph M. Navari</bold>: concept and design, collection and/or assembly of data, data interpretation, manuscript drafting and critical review, final approval of manuscript.</p><p><bold>Timothy Tyler</bold>: concept and design, collection and/or assembly of data, data interpretation, manuscript drafting and critical review, final approval of manuscript.</p><p><bold>Naoki Inui</bold>: data interpretation, manuscript drafting and critical review, final approval of manuscript.</p><p><bold>Hirotoshi Iihara</bold>: data interpretation, manuscript drafting and critical review, final approval of manuscript.</p><p><bold>Erminio Bonizzoni</bold>: concept and design, collection and/or assembly of data, data analysis and interpretation, manuscript drafting and critical review, final approval of manuscript.</p><p><bold>Yeon Hee Park</bold>: data interpretation, manuscript drafting and critical review, final approval of manuscript.</p><p><bold>Hope S. Rugo</bold>: data interpretation, manuscript drafting and critical review, final approval of manuscript.</p><p><bold>Eric J. Roeland</bold>: data interpretation, manuscript drafting and critical review, final approval of manuscript.</p></sec><sec sec-type="COI-statement" disp-level="1" id="s0008"><title>Disclosure statement</title><p><bold>R. M. Navari</bold> reports no competing interests.</p><p><bold>T. Tyler</bold> reports participating in speaker&#8217;s bureaus for BMS, Amgen, Sanofi Genzyme, Incyte, and Pharmacosmos and reports receiving consultancy fees from Pfizer Oncology, AstraZeneca, TerSera, and Sandoz.</p><p><bold>N. Inui</bold> reports participating in speakers&#8217; bureaus for Chugai Pharmaceutical, Lilly, Nippon Boehringer Ingelheim, Novartis, Taiho Pharmaceutical, AstraZeneca, Takeda Pharmaceutical, Amgen, and Merck and reports receiving research funding from Chugai Pharmaceutical, Nippon Boehringer Ingelheim, Taiho Pharmaceutical, AstraZeneca (Inst), and Kyowa Kirin International.</p><p><bold>H. Iihara</bold> reports having received personal fees from Astellas Pharma Co., Ltd., AstraZeneca plc, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly and Company, Nippon Kayaku Co., Ltd., Ohara Pharmaceutical Co.,Ltd., Sawai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Yakult Honsha Co., Ltd., outside the submitted work.</p><p><bold>E. Bonizzoni</bold> reports receiving consultancy fees from Helsinn Healthcare and Zambon Biotech.</p><p><bold>Y. H. Park</bold> reports receiving grants from MSD, Pfizer, AstraZeneca, Gencurix, Roche, Novartis, and Inocras; receiving consultancy or advisory board fees from AstraZeneca, MSD, Pfizer, Eisai, Lilly, Roche, Gilead, Daiichi-Sankyo, Helsinn MENARINI, Novartis, and EVEREST; receiving manuscript fees from AstraZeneca, Pfizer, Roche, MSD, Daiichi-Sankyo, Novartis, and Gilead; and receiving honoraria from AstraZeneca, MSD, Pfizer, Roche, Daiichi-Sankyo, Novartis, Gilead, and Helsinn. Dr. Park also reports receiving support for attending meetings or for travel from Gilead, Pfizer, and AstraZeneca, and receiving research funding from AstraZeneca, Pfizer, MSD, and Daewoong or for contract research from AstraZeneca, Pfizer, MSD, and Kirin.</p><p><bold>H. S. Rugo</bold> reports receiving consultancy/advisory fees from Napo, and Helsinn and receiving institutional research support to her former institution (UCSF) from AstraZeneca, Daiichi Sankyo, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., Gilead Sciences, Inc., Lilly; Merck &amp; Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, and Ambryx.</p><p><bold>E. J. Roeland</bold> reports being a member of the scientific advisory board for Pfizer, Napo Pharmaceuticals, and Aveo Pharmaceuticals; consultant for Dexcel Pharma, and Ryvu Therapeutics; research funding Napo Pharmaceuticals, Pfizer (all to institution); and expert witness for Heron Therapeutics.</p><p>Editorial and medical writing assistance was provided by Jennifer Vanden Burgt, an independent consultant from Minneapolis, MN, and funded by Helsinn Healthcare SA, Lugano, Switzerland.</p></sec><sec disp-level="1" id="s0009"><title>Reviewer disclosures</title><p>Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.</p></sec><sec disp-level="1" id="s0010"><title>Ethical conduct of research</title><p>All included studies reported that the protocols were approved by institutional review boards<italic toggle="yes">/</italic>independent ethics committees and all patients provided written informed consent before treatment initiation. The studies were conducted in compliance with Good Clinical Practice, the principles of the Declaration of Helsinki, and the International Conference on Harmonization guidelines.</p></sec><sec sec-type="supplementary-material" disp-level="1" id="s0011"><title>Supplementary Material</title><p>Supplemental data for this article can be accessed online at <ext-link xlink:href="https://doi.org/10.1080/14796694.2025.2542108" ext-link-type="uri">https://doi.org/10.1080/14796694.2025.2542108</ext-link></p></sec><ref-list><title>References</title><p>
<bold>Papers of special note have been highlighted as either of interest (&#8226;) or of considerable interest (&#8226;&#8226;) to readers.</bold>
</p><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bo&#353;njak</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Gralla</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Schwartzberg</surname><given-names>L.</given-names></string-name></person-group><article-title>Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK(1)) receptor antagonists</article-title>. <source>Support Care Cancer</source>. <year>2017</year>;<volume>25</volume>(<issue>5</issue>):<fpage>1661</fpage>&#8211;<lpage>1671</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00520-017-3585-z</pub-id><pub-id pub-id-type="pmid">28108820</pub-id><pub-id pub-id-type="pmcid">PMC5378744</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bianchini</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Arpino</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Biganzoli</surname><given-names>L</given-names></string-name>, et al</person-group>. <article-title>Emetogenicity of antibody-drug conjugates (ADCs) in solid tumors with a focus on Trastuzumab Deruxtecan: insights from an Italian expert panel</article-title>. <source>Cancers (Basel)</source>. <year>2022</year>;<volume>14</volume>(<issue>4</issue>):<fpage>1022</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cancers14041022</pub-id><pub-id pub-id-type="pmid">35205771</pub-id><pub-id pub-id-type="pmcid">PMC8870408</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rugo</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Bianchini</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Cortes</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer</article-title>. <source>ESMO Open</source>. <year>2022</year>;<volume>7</volume>(<issue>4</issue>):<fpage>100553</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.esmoop.2022.100553</pub-id><pub-id pub-id-type="pmid">35964548</pub-id><pub-id pub-id-type="pmcid">PMC9375150</pub-id></mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bianchini</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Rugo</surname><given-names>HS</given-names></string-name>, et al</person-group>. <article-title>291P perceptions of antibody drug conjugate (ADC)-induced nausea and vomiting: results of a survey of healthcare providers at ESMO</article-title>. <source>ESMO Open</source>. <year>2024</year>;<volume>9</volume>:<fpage>103348</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.esmoop.2024.103348</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hesketh</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Kris</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Basch</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Antiemetics: ASCO guideline update</article-title>. <source>J Clin Oncol</source>. <year>2020</year>;<volume>38</volume>(<issue>24</issue>):<fpage>2782</fpage>&#8211;<lpage>2797</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.20.01296</pub-id><pub-id pub-id-type="pmid">32658626</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Herrstedt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Celio</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hesketh</surname><given-names>PJ</given-names></string-name>, et al</person-group>. <article-title>2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents</article-title>. <source>Support Care Cancer</source>. <year>2023</year>;<volume>32</volume>(<issue>1</issue>):<fpage>47</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s00520-023-08221-4</pub-id><pub-id pub-id-type="pmid">38127246</pub-id><pub-id pub-id-type="pmcid">PMC10739516</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>NCCN</collab></person-group>. <article-title>NCCN clinical practice guidelines in Oncology (NCCN guidelines version 2.2025)</article-title>. <year>2025</year>. <comment>Available from:</comment><ext-link xlink:href="https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf" ext-link-type="uri">https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf</ext-link></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Herrstedt</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Clark-Snow</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ruhlmann</surname><given-names>CH</given-names></string-name>, et al</person-group>. <article-title>2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting</article-title>. <source>ESMO Open</source>. <year>2024</year>;<volume>9</volume>(<issue>2</issue>):<fpage>102195</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.esmoop.2023.102195</pub-id><pub-id pub-id-type="pmid">38458657</pub-id><pub-id pub-id-type="pmcid">PMC10937211</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="webpage"><article-title>AKYNZEO (netupitant/palonosetron) capsules for oral use; AKYNZEO (fosnetupitant/palonosetron) for injection, for intravenous use, Prescribing information 2023</article-title>. <comment>Available from:</comment><ext-link xlink:href="https://www.akynzeo.com/assets/pdf/Akynzeo-USPI.pdf" ext-link-type="uri">https://www.akynzeo.com/assets/pdf/Akynzeo-USPI.pdf</ext-link></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Akynzeo Summary of Product Characteristics 2020</collab></person-group>. <year>2024</year>. <comment>Available from:</comment><ext-link xlink:href="https://www.ema.europa.eu/en/documents/product-information/akynzeo-epar-product-information_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/product-information/akynzeo-epar-product-information_en.pdf</ext-link></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>EMEND (aprepitant) capsules for oral use, Prescribing Information</collab></person-group>. <year>2022</year>. <comment>Available from:</comment><ext-link xlink:href="https://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf" ext-link-type="uri">https://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf</ext-link></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>VARUBI (rolapitant) tablets for oral use; Prescribing Information</collab></person-group>. <year>2017</year>. <comment>Available from:</comment><ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208399s000lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208399s000lbl.pdf</ext-link></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>EMEND (fosaprepitant) for injection for intravenous use, Prescribing Information</collab></person-group>. <year>2022</year>. <comment>Available from:</comment><ext-link xlink:href="https://www.merck.com/product/usa/pi_circulars/e/emend_iv/emend_iv_lowedta_pi.pdf" ext-link-type="uri">https://www.merck.com/product/usa/pi_circulars/e/emend_iv/emend_iv_lowedta_pi.pdf</ext-link></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>dos Santos</surname><given-names>LV</given-names></string-name>, <string-name name-style="western"><surname>Souza</surname><given-names>FH</given-names></string-name>, <string-name name-style="western"><surname>Brunetto</surname><given-names>AT</given-names></string-name>, et al</person-group>. <article-title>Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review</article-title>. <source>J Natl Cancer Inst</source>. <year>2012</year>;<volume>104</volume>(<issue>17</issue>):<fpage>1280</fpage>&#8211;<lpage>1292</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jnci/djs335</pub-id><pub-id pub-id-type="pmid">22911671</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jordan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Warr</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Hinke</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Defining the efficacy of neurokinin-1 receptor antagonists in controlling chemotherapy-induced nausea and vomiting in different emetogenic settings&#8212;a meta-analysis [original]</article-title>. <source>Support Care Cancer</source>. <year>2016</year>;<volume>24</volume>(<issue>5</issue>):<fpage>1941</fpage>&#8211;<lpage>1954</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00520-015-2990-4</pub-id><pub-id pub-id-type="pmid">26476625</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yuan</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, et al</person-group>. <article-title>Efficacy and safety of neurokinin-1 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting: systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Asian Pac J Cancer Prev</source>. <year>2016</year>;<volume>17</volume>(<issue>4</issue>):<fpage>1661</fpage>&#8211;<lpage>1675</lpage>. doi: <pub-id pub-id-type="doi">10.7314/APJCP.2016.17.4.1661</pub-id><pub-id pub-id-type="pmid">27221836</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)</article-title>. <source>Ann Oncol</source>. <year>2018</year>;<volume>29</volume>(<issue>2</issue>):<fpage>452</fpage>&#8211;<lpage>458</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdx698</pub-id><pub-id pub-id-type="pmid">29092012</pub-id><pub-id pub-id-type="pmcid">PMC5834144</pub-id></mixed-citation><note><p>
<bold>&#8226;&#8226; This randomized comparative study was included in this IPD meta-analysis.</bold>
</p></note></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hata</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Okamoto</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Inui</surname><given-names>N</given-names></string-name>, et al</person-group>. <article-title>Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE</article-title>. <source>J Clin Oncol</source>. <year>2022</year>;<volume>40</volume>(<issue>2</issue>):<fpage>180</fpage>&#8211;<lpage>188</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.21.01315</pub-id><pub-id pub-id-type="pmid">34793245</pub-id><pub-id pub-id-type="pmcid">PMC8718175</pub-id></mixed-citation><note><p>
<bold>&#8226;&#8226; This randomized comparative study was included in this IPD meta-analysis.</bold>
</p></note></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zelek</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Debourdeau</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bourgeois</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>A pragmatic study evaluating NEPA versus aprepitant for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy</article-title>. <source>Oncologist</source>. <year>2021</year>;<volume>26</volume>(<issue>10</issue>):<fpage>e1870</fpage>&#8211;<lpage>e1879</lpage>. doi: <pub-id pub-id-type="doi">10.1002/onco.13888</pub-id><pub-id pub-id-type="pmid">34216177</pub-id><pub-id pub-id-type="pmcid">PMC8488783</pub-id></mixed-citation><note><p>
<bold>&#8226;&#8226; This randomized comparative study was included in this IPD meta-analysis.</bold>
</p></note></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Piechotta</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Haque</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2021</year>;<volume>11</volume>(<issue>11</issue>):<fpage>Cd012775</fpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD012775.pub2</pub-id><pub-id pub-id-type="pmid">34784425</pub-id><pub-id pub-id-type="pmcid">PMC8594936</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Navari</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Binder</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Bonizzoni</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis</article-title>. <source>Future Oncol</source>. <year>2021</year>;<volume>17</volume>(<issue>23</issue>):<fpage>3027</fpage>&#8211;<lpage>3035</lpage>. doi: <pub-id pub-id-type="doi">10.2217/fon-2021-0023</pub-id><pub-id pub-id-type="pmid">33878896</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Cochrane. About IPD Meta-analyses</collab></person-group>. <year>2024</year> [<date-in-citation>cited 2024 <month>Sep</month><day>16</day></date-in-citation>]. <comment>Available from:</comment><ext-link xlink:href="https://methods.cochrane.org/ipdma/about-ipd-meta-analyses" ext-link-type="uri">https://methods.cochrane.org/ipdma/about-ipd-meta-analyses</ext-link></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Page</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></string-name>, et al</person-group>. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source>. <year>2021</year>;<volume>372</volume>:<fpage>n71</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stewart</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rovers</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Preferred reporting Items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement</article-title>. <source>JAMA</source>. <year>2015</year>;<volume>313</volume>(<issue>16</issue>):<fpage>1657</fpage>&#8211;<lpage>1665</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2015.3656</pub-id><pub-id pub-id-type="pmid">25919529</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jordan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gralla</surname><given-names>RJ</given-names></string-name>, et al</person-group>. <article-title>2016 updated MASCC/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents</article-title>. <source>Support Care Cancer</source>. <year>2017</year>;<volume>25</volume>(<issue>1</issue>):<fpage>271</fpage>&#8211;<lpage>275</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00520-016-3332-x</pub-id><pub-id pub-id-type="pmid">27501965</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tierney</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Vale</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Riley</surname><given-names>R</given-names></string-name>, et al</person-group>. <article-title>Individual participant data (IPD) meta-analyses of randomised controlled trials: guidance on their use</article-title>. <source>PLOS Med</source>. <year>2015</year>;<volume>12</volume>(<issue>7</issue>):<fpage>e1001855</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pmed.1001855</pub-id><pub-id pub-id-type="pmid">26196287</pub-id><pub-id pub-id-type="pmcid">PMC4510878</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>B&#246;rjeson</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hursti</surname><given-names>TJ</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale</article-title>. <source>Cancer Nurs</source>. <year>1997</year>;<volume>20</volume>(<issue>4</issue>):<fpage>260</fpage>&#8211;<lpage>266</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00002820-199708000-00005</pub-id><pub-id pub-id-type="pmid">9265812</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Riley</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Ensor</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hattle</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Two-stage or not two-stage? That is the question for IPD meta-analysis projects</article-title>. <source>Res Synth Methods</source>. <year>2023</year>;<volume>14</volume>(<issue>6</issue>):<fpage>903</fpage>&#8211;<lpage>910</lpage>. doi: <pub-id pub-id-type="doi">10.1002/jrsm.1661</pub-id><pub-id pub-id-type="pmid">37606180</pub-id><pub-id pub-id-type="pmcid">PMC7615283</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McNutt</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname><given-names>X</given-names></string-name>, et al</person-group>. <article-title>Estimating the relative risk in cohort studies and clinical trials of common outcomes</article-title>. <source>Am J Epidemiol</source>. <year>2003</year>;<volume>157</volume>(<issue>10</issue>):<fpage>940</fpage>&#8211;<lpage>943</lpage>. doi: <pub-id pub-id-type="doi">10.1093/aje/kwg074</pub-id><pub-id pub-id-type="pmid">12746247</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Houwelingen</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Arends</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Stijnen</surname><given-names>T</given-names></string-name></person-group>. <article-title>Advanced methods in meta-analysis: multivariate approach and meta-regression</article-title>. <source>Stat Med</source>. <year>2002</year>;<volume>21</volume>(<issue>4</issue>):<fpage>589</fpage>&#8211;<lpage>624</lpage>. doi: <pub-id pub-id-type="doi">10.1002/sim.1040</pub-id><pub-id pub-id-type="pmid">11836738</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gralla</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Bosnjak</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Hontsa</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy</article-title>. <source>Ann Oncol</source>. <year>2014</year>;<volume>25</volume>(<issue>7</issue>):<fpage>1333</fpage>&#8211;<lpage>1339</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdu096</pub-id><pub-id pub-id-type="pmid">24631949</pub-id><pub-id pub-id-type="pmcid">PMC4071753</pub-id></mixed-citation><note><p>
<bold>&#8226;&#8226; This randomized comparative study was included in this IPD meta-analysis.</bold>
</p></note></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hata</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shiraishi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Inui</surname><given-names>N</given-names></string-name>, et al</person-group>. <article-title>Exploratory analysis comparing fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blind, phase 3 study (CONSOLE)</article-title>. <source>Oncol Ther</source>. <year>2022</year>;<volume>10</volume>(<issue>1</issue>):<fpage>253</fpage>&#8211;<lpage>262</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40487-022-00188-2</pub-id><pub-id pub-id-type="pmid">35246827</pub-id><pub-id pub-id-type="pmcid">PMC9098704</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hesketh</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Rossi</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rizzi</surname><given-names>G</given-names></string-name>, et al</person-group>. <article-title>Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study</article-title>. <source>Ann Oncol</source>. <year>2014</year>;<volume>25</volume>(<issue>7</issue>):<fpage>1340</fpage>&#8211;<lpage>1346</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdu110</pub-id><pub-id pub-id-type="pmid">24608196</pub-id><pub-id pub-id-type="pmcid">PMC4071755</pub-id></mixed-citation><note><p>
<bold>&#8226;&#8226; This randomized comparative study was included in this IPD meta-analysis.</bold>
</p></note></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Matsuura</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tsurutani</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Inoue</surname><given-names>K</given-names></string-name>, et al</person-group>. <article-title>A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC</article-title>. <source>Cancer</source>. <year>2022</year>;<volume>128</volume>(<issue>8</issue>):<fpage>1692</fpage>&#8211;<lpage>1698</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cncr.34088</pub-id><pub-id pub-id-type="pmid">35045185</pub-id><pub-id pub-id-type="pmcid">PMC9306508</pub-id></mixed-citation><note><p>
<bold>&#8226;&#8226; This randomized comparative study was included in this IPD meta-analysis.</bold>
</p></note></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>XM</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>XR</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>ZH</given-names></string-name>, et al</person-group>. <article-title>A brief introduction of meta-analyses in clinical practice and research</article-title>. <source>J Gene Med</source>. <year>2021</year>;<volume>23</volume>(<issue>5</issue>):<fpage>e3312</fpage>. doi: <pub-id pub-id-type="doi">10.1002/jgm.3312</pub-id><pub-id pub-id-type="pmid">33450104</pub-id><pub-id pub-id-type="pmcid">PMC8243934</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thomas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Radji</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Benedetti</surname><given-names>A</given-names></string-name></person-group>. <article-title>Systematic review of methods for individual patient data meta- analysis with binary outcomes</article-title>. <source>BMC Med Res Methodol</source>. <year>2014</year>;<volume>14</volume>(<issue>1</issue>):<fpage>79</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2288-14-79</pub-id><pub-id pub-id-type="pmid">24943877</pub-id><pub-id pub-id-type="pmcid">PMC4074845</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aapro</surname><given-names>M</given-names></string-name></person-group>. <article-title>CINV: still troubling patients after all these years</article-title>. <source>Support Care Cancer</source>. <year>2018</year>;<volume>26</volume>(<issue>Suppl S1</issue>):<fpage>5</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00520-018-4131-3</pub-id><pub-id pub-id-type="pmid">29556808</pub-id><pub-id pub-id-type="pmcid">PMC5876280</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chow</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>LB</given-names></string-name>, <string-name name-style="western"><surname>Baqri</surname><given-names>W</given-names></string-name>, et al</person-group>. <article-title>Prevalence and predictors of long-delayed (&gt;&#8201;120&#160;h) chemotherapy-induced nausea and vomiting (CINV)&#8212;a systematic review and individual patient data meta-analysis</article-title>. <source>Support Care Cancer</source>. <year>2023</year>;<volume>31</volume>(<issue>8</issue>):<fpage>505</fpage>. doi: <pub-id pub-id-type="doi">10.1007/s00520-023-07978-y</pub-id><pub-id pub-id-type="pmid">37535218</pub-id></mixed-citation><note><p>
<bold>&#8226; This systematic review evaluated articles assessing long-delayed (&gt;120 hour) CINV and showed 31% and 24% of patients receiving HEC and MEC, respectively, experiencing long-delayed nausea. Patients with delayed CINV, specifically on days 4&#8211;5, were at increased risk of experiencing long-delayed CINV.</bold>
</p></note></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="confproc"><person-group person-group-type="author"><string-name name-style="western"><surname>Aapro</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Iihara</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Olivari Tilola</surname><given-names>S</given-names></string-name></person-group>, et al. <article-title>Model-predicted Neurokinin-1 (NK1) receptor occupancy of netupitant versus aprepitant over an extended time period: implications for controlling nausea and vomiting associated with Antibody-Drug Conjugates (ADCs) [abstract]</article-title>. In: <conf-name>Proceedings of the San Antonio Breast Cancer Symposium 2024</conf-name>; <conf-date>2024 Dec 10&#8211;13</conf-date>; <conf-loc>San Antonio, TX</conf-loc>. <publisher-loc>Philadelphia (PA)</publisher-loc>: <publisher-name>AACR</publisher-name>; <year>2024</year>; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P1-04-03.</mixed-citation><note><p>
<bold>&#8226; This analysis compared the NK1 receptor occupancy of single-dose netupitant to repeated and single-dose aprepitant over a time period equivalent to a treatment cycle. The results showed that netupitant maintains receptor occupancy for a substantially longer duration than aprepitant.</bold>
</p></note></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stathis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pietra</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Rojas</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Inhibition of substance P-mediated responses in NG108&#8211;15 cells by netupitant and palonosetron exhibit synergistic effects</article-title>. <source>Eur J Pharmacol</source>. <year>2012</year>;<volume>689</volume>(<issue>1&#8211;3</issue>):<fpage>25</fpage>&#8211;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejphar.2012.05.037</pub-id><pub-id pub-id-type="pmid">22683863</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thomas</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Stathis</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rojas</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Netupitant and palonosetron trigger NK1 receptor internalization in NG108&#8211;15 cells</article-title>. <source>Exp Brain Res</source>. <year>2014</year>;<volume>232</volume>(<issue>8</issue>):<fpage>2637</fpage>&#8211;<lpage>2644</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00221-014-4017-7</pub-id><pub-id pub-id-type="pmid">24969614</pub-id><pub-id pub-id-type="pmcid">PMC4112047</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rojas</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Alt</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function</article-title>. <source>Eur J Pharmacol</source>. <year>2010</year>;<volume>626</volume>(<issue>2&#8211;3</issue>):<fpage>193</fpage>&#8211;<lpage>199</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejphar.2009.10.002</pub-id><pub-id pub-id-type="pmid">19836386</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Inui</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Toi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yoneshima</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Pooled analysis of studies evaluating fosnetupitant and risk factors for cisplatin-induced nausea and vomiting during the extended overall phase</article-title>. <source>Adv Ther</source>. <year>2023</year>;<volume>40</volume>(<issue>11</issue>):<fpage>4928</fpage>&#8211;<lpage>4944</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12325-023-02648-1</pub-id><pub-id pub-id-type="pmid">37715851</pub-id><pub-id pub-id-type="pmcid">PMC10567891</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zelek</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Navari</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Aapro</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy</article-title>. <source>Cancer Med</source>. <year>2023</year>;<volume>12</volume>(<issue>15</issue>):<fpage>15769</fpage>&#8211;<lpage>15776</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cam4.6121</pub-id><pub-id pub-id-type="pmid">37537943</pub-id><pub-id pub-id-type="pmcid">PMC10469631</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Detlefsen</surname><given-names>S</given-names></string-name></person-group>. <article-title>Safety and antiemetic efficacy of weekly administration of palonosetron/netupitant plus dexamethasone during five weeks of concomitant Chemo-radiation [abstract]</article-title>. <source>Support Care Cancer</source>. <year>2024</year>;<volume>32</volume>(<issue>1</issue>):<fpage>434</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00520-025-09573-9</pub-id><pub-id pub-id-type="pmcid">PMC12119652</pub-id><pub-id pub-id-type="pmid">40437122</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Verma</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Pednekar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Barkate</surname><given-names>HB</given-names></string-name>, et al</person-group>. <article-title>Effectiveness of intravenous fosnetupitant &amp; palonosetron for cinv prophylaxis in patients receiving highly emetogenic chemotherapy regimens: subgroup analysis from a phase IV Indian study</article-title>. <source>ESMO Congr Barcelona Spain Ann Oncol</source>. <year>2024</year>;<volume>35</volume>:<fpage>S1077</fpage>&#8211;<lpage>S1114</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.annonc.2024.08.1973</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sakai</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tsurutani</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ozaki</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)</article-title>. <source>Ann Oncol</source>. <year>2024</year>;<volume>36</volume>(<issue>1</issue>):<fpage>31</fpage>&#8211;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.annonc.2024.09.001</pub-id><pub-id pub-id-type="pmid">39284382</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Services USDoHaH</collab></person-group>. <article-title>Common terminology criteria for adverse events (CTCAE) v5.0: National Institutes of Health</article-title>. <publisher-name>National Cancer Institute</publisher-name>; <year>2017</year> [<date-in-citation>cited 2025 <month>Apr</month><day>22</day></date-in-citation>]. <comment>Available from:</comment><ext-link xlink:href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm" ext-link-type="uri">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm</ext-link></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ueno</surname><given-names>NT</given-names></string-name>, <string-name name-style="western"><surname>Jacot</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Yamashita</surname><given-names>T</given-names></string-name>, et al</person-group>. <article-title>217O patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician&#8217;s choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)</article-title>. <source>Ann Oncol</source>. <year>2022</year>;<volume>33</volume>:<fpage>S632</fpage>&#8211;<lpage>S633</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.annonc.2022.07.256</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Perachino</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Blondeaux</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Molinelli</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>290P adverse events (AEs) and impact on quality of life (QoL) of antibody-drug conjugates (ADC) in the treatment of metastatic breast cancer (mBC): a systematic review and meta-analysis of randomized controlled trials (RCTs)</article-title>. <source>ESMO Open</source>. <year>2024</year>;<volume>9</volume>:<fpage>103347</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.esmoop.2024.103347</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>